{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:06:34Z","timestamp":1792026394720,"version":"4.4.0"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["2023YFC3603300"],"award-info":[{"award-number":["2023YFC3603300"]}],"id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202201AS070038"],"award-info":[{"award-number":["202201AS070038"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202305AH340006"],"award-info":[{"award-number":["202305AH340006"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["xbzg-zdsys-202312"],"award-info":[{"award-number":["xbzg-zdsys-202312"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471599"],"award-info":[{"award-number":["82471599"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmthera.2026.109055","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:19Z","timestamp":1780717999000},"page":"109055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting BRD4 to reverse organ fibrosis: Epigenetic regulation, cellular plasticity, and therapeutic potential"],"prefix":"10.1016","volume":"285","author":[{"given":"Ayesha","family":"Nisar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109055_bb0005","doi-asserted-by":"crossref","first-page":"11660","DOI":"10.1038\/s41467-025-66597-9","article-title":"Identification of epigenetic regulators of fibrotic transformation in cardiac fibroblasts through bulk and single-cell CRISPR screens","volume":"16","author":"Aguado-Alvaro","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-024-08085-6","article-title":"Chromatin remodelling drives immune cell-fibroblast communication in heart failure","volume":"635","author":"Alexanian","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.chemrev.7b00181","article-title":"Lysine acetylation Goes global: From epigenetics to metabolism and therapeutics","volume":"118","author":"Ali","year":"2018","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0020","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/ijms26073063","article-title":"Correction: Almeida et al. Cell reprogramming, transdifferentiation, and dedifferentiation approaches for heart repair","volume":"26","author":"Almeida","year":"2025","journal-title":"International Journal of Molecular Sciences 2025"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0025","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1161\/ATVBAHA.121.313788","article-title":"Endothelial-mesenchymal transition in cardiovascular disease","volume":"41","author":"Alvandi","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1345492","article-title":"Azacitidine induced lung injury: Report and contemporary discussion on diagnosis and management","volume":"14","author":"Alyamany","year":"2024","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138687","article-title":"BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy","volume":"5","author":"Antolic","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2021.06.026","article-title":"A BRD4-mediated elongation control point primes transcribing RNA polymerase II for 3\u2032-processing and termination","volume":"81","author":"Arnold","year":"2021","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0055","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1172\/JCI135922","article-title":"BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific Lamin A\/C-deficient mice","volume":"130","author":"Auguste","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/HYPERTENSIONAHA.123.21364","article-title":"Alternative renin-angiotensin system","volume":"81","author":"Bader","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0065","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/sj.emboj.7600883","article-title":"Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb","volume":"24","author":"Barboric","year":"2005","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106570","article-title":"Changes in nascent chromatin structure regulate activation of the pro-fibrotic transcriptome and myofibroblast emergence in organ fibrosis","volume":"26","author":"Basta","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199476","article-title":"Shared and context-specific mechanisms of EMT and cellular plasticity in cancer and fibrotic diseases","volume":"26","author":"Bastos","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0080","first-page":"530","article-title":"Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer","volume":"11","author":"Bauer","year":"2021","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107479","article-title":"Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors","volume":"208","author":"Bechter","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2022.842558","article-title":"Selective inhibition of Bromodomain-containing protein 4 reduces Myofibroblast Transdifferentiation and pulmonary fibrosis","volume":"2","author":"Bernau","year":"2022","journal-title":"Frontiers in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213336","article-title":"Angiotensin II-induced signal transduction mechanisms for cardiac hypertrophy","volume":"11","author":"Bhullar","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-026-04036-7","article-title":"Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition","volume":"24","author":"Bi","year":"2026","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.pharmthera.2026.109055_bb0110","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1093\/nar\/gki997","article-title":"Oligomerization of HEXIM1 via 7SK snRNA and coiled-coil region directs the inhibition of P-TEFb","volume":"33","author":"Blazek","year":"2005","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drudis.2019.11.002","article-title":"Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling","volume":"25","author":"Brasier","year":"2020","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0125","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1111\/jcmm.13787","article-title":"CXCL6-EGFR-induced Kupffer cells secrete TGF-\u03b21 promoting hepatic stellate cell activation via the SMAD2\/BRD4\/C-MYC\/EZH2 pathway in liver fibrosis","volume":"22","author":"Cai","year":"2018","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Critical Reviews in Oncogenesis"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0135","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1097\/TP.0000000000003319","article-title":"BET protein inhibition prolongs cardiac transplant survival via enhanced myocardial autophagy","volume":"104","author":"Chen","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0140","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/jcp.25797","article-title":"Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis","volume":"232","author":"Chen","year":"2017","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115497","article-title":"BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300\/H3K27ac\/PLK1 axis","volume":"210","author":"Cheng","year":"2023","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.668708","article-title":"Sinapic acid reduces oxidative stress and pyroptosis via inhibition of BRD4 in alcoholic liver disease","volume":"12","author":"Chu","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0155","series-title":"BRD4-MK2 signaling: Target for Crohn\u2019s disease-associated fibrosis","volume":"36","author":"Chulkina","year":"2022"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0160","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ecco-jcc\/jjae009","article-title":"Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation-associated fibrosis in Crohn\u2019s disease","volume":"18","author":"Chulkina","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0165","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0022-2019","article-title":"Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis","volume":"28","author":"Collins","year":"2019","journal-title":"European Respiratory Review"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.07.025","article-title":"The short isoform of BRD4 promotes HIV-1 latency by engaging repressive SWI\/SNF chromatin-remodeling complexes","volume":"67","author":"Conrad","year":"2017","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0175","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0180","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1189\/jlb.2RI0616-250R","article-title":"Bromodomain 4: A cellular Swiss army knife","volume":"100","author":"Devaiah","year":"2016","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0185","doi-asserted-by":"crossref","first-page":"8758","DOI":"10.1073\/pnas.1433065100","article-title":"The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis","volume":"100","author":"Dey","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsptsci.3c00219","article-title":"Apabetalone (RVX-208): A potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders","volume":"7","author":"Dhulkifle","year":"2024","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0195","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0200","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0205","series-title":"BRD4 is a Novel Therapeutic Target for Liver Fibrosis","first-page":"15713","volume":"112","author":"Ding","year":"2015"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12931-023-02348-y","article-title":"BRD4 is involved in viral exacerbation of chronic obstructive pulmonary disease","volume":"24","author":"Duan","year":"2023","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0215","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1038\/s41598-018-31658-1","article-title":"Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells","volume":"8","author":"Ebine","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0220","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacbts.2018.05.003","article-title":"Epigenetics in cardiac fibrosis: Emphasis on inflammation and fibroblast activation","volume":"3","author":"Felisbino","year":"2018","journal-title":"JACC Basic Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-023-00696-6","article-title":"Pelabresib (CPI-0610): An exciting novel drug for the treatment of myelofibrosis","volume":"18","author":"Ferreira Gomes","year":"2023","journal-title":"Current Hematologic Malignancy Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0240","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0245","article-title":"Bromodomain-containing protein 4 in inflammatory diseases: Molecular mechanisms and therapeutic potential","volume":"23","author":"Frascatani","year":"2026","journal-title":"Journal of Inflammation (Lond)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.acr.2016.04.001","article-title":"Small-molecule targeting of BET proteins in cancer","volume":"131","author":"French","year":"2016","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0255","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1080\/21655979.2022.2066756","article-title":"Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis","volume":"13","author":"Fu","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113853","article-title":"Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins","volume":"226","author":"Fu","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0265","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0270","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin","volume":"139","author":"Gallant-Behm","year":"2019","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0275","doi-asserted-by":"crossref","DOI":"10.1172\/JCI196730","article-title":"Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis","author":"Gan","year":"2026","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0280","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/hep.31617","article-title":"Endothelial p300 promotes portal hypertension and hepatic fibrosis through C-C motif chemokine ligand 2-mediated angiocrine signaling","volume":"73","author":"Gao","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0285","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061663","article-title":"Apabetalone downregulates fibrotic, inflammatory and calcific processes in renal mesangial cells and patients with renal impairment","volume":"11","author":"Gilham","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0295","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ajpath.2016.01.018","article-title":"Mechanisms of lung fibrosis resolution","volume":"186","author":"Glasser","year":"2016","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006272","article-title":"Acetylation reader proteins: Linking acetylation signaling to genome maintenance and cancer","volume":"12","author":"Gong","year":"2016","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2021.112620","article-title":"The epigenetic regulator BRD4 is involved in cadmium-triggered inflammatory response in rat kidney","volume":"224","author":"Gong","year":"2021","journal-title":"Ecotoxicology and Environmental Safety"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2021.127110","article-title":"Epigenetic regulator BRD4 is involved in cadmium-induced acute kidney injury via contributing to lysosomal dysfunction, autophagy blockade and oxidative stress","volume":"423","author":"Gong","year":"2022","journal-title":"Journal of Hazardous Materials"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0315","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12951-024-02967-7","article-title":"Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy","volume":"22","author":"Guan","year":"2024","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.pharmthera.2026.109055_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: Biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.taap.2018.05.018","article-title":"BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy","volume":"352","author":"Guo","year":"2018","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0330","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001742","article-title":"Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH","author":"Guo","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0335","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cvr\/cvae021","article-title":"Endothelial to mesenchymal transition: At the axis of cardiovascular health and disease","volume":"120","author":"Hall","year":"2024","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0340","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1111\/febs.15693","article-title":"Metabolic requirements of pulmonary fibrosis: Role of fibroblast metabolism","volume":"288","author":"Hamanaka","year":"2021","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291469","article-title":"Fucoxanthin inhibits cardiac fibroblast transdifferentiation by alleviating oxidative stress through downregulation of BRD4","volume":"18","author":"Han","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0350","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116904","article-title":"Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues","volume":"279","author":"Hassan","year":"2024","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0360","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejpb.2018.11.018","article-title":"Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis","volume":"134","author":"Hassan","year":"2019","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0365","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.apsb.2021.07.018","article-title":"Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis","volume":"12","author":"He","year":"2023","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0370","first-page":"PA3914","article-title":"Intratracheal administration of a PROTAC with subnanomolar potency induces BRD4 degradation in the lung without systemic target engagement","volume":"62","author":"Hedstr\u00f6m","year":"2026","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0375","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: From mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0380","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1007\/s00125-025-06541-0","article-title":"I-BET151 modulates glucokinase gene expression and beta cell function in part through changes in FOXO1 expression","volume":"68","author":"Ho","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41419-022-05505-1","article-title":"Regulation of programmed cell death by Brd4","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0395","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0400","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1074\/jbc.RA117.001518","article-title":"Bromodomain-containing protein 4-independent transcriptional activation by autoimmune regulator (AIRE) and NF-\u03baB","volume":"293","author":"Huang","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0405","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7150\/ijms.29930","article-title":"MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation","volume":"16","author":"Huang","year":"2019","journal-title":"International Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0410","series-title":"Epithelial\u2013mesenchymal Transition: The History, Regulatory Mechanism, and Cancer Therapeutic Opportunities","first-page":"e144","volume":"3","author":"Huang","year":"2022"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0415","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1038\/s41467-025-63594-w","article-title":"Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9","volume":"16","author":"Hughes","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0420","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8797206","article-title":"HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116059","article-title":"BET protein-mediated transcriptional regulation in heart failure","volume":"22","author":"Ijaz","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0430","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: How they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0435","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0440","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/genes3020320","article-title":"The role of bromodomain proteins in regulating gene expression","volume":"3","author":"Josling","year":"2012","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102057","article-title":"CG223, a novel BET inhibitor, exerts TGF-\u03b21-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis","volume":"70","author":"Kaneshita","year":"2021","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0450","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2023.03.235","article-title":"The epigenetic reader, Bromodomain containing 2, mediates Cholangiocyte senescence via interaction with ETS proto-oncogene 1","volume":"165","author":"Kang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88032","article-title":"BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo","volume":"2","author":"Kumar","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0460","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf1406","article-title":"The BRD4-nucleosome interaction is enhanced modestly and non-selectively by histone acetylation","volume":"53","author":"Lambrechts","year":"2025","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0465","doi-asserted-by":"crossref","first-page":"8518","DOI":"10.1111\/jcmm.15473","article-title":"Salvianic acid A alleviates chronic alcoholic liver disease by inhibiting HMGB1 translocation via down-regulating BRD4","volume":"24","author":"Lan","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0470","first-page":"26","article-title":"Endothelial-to-mesenchymal transition in post-myocardial infarction fibrosis: A maladaptive but targetable pathway","volume":"37","author":"Le","year":"2026","journal-title":"Ejifcc"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0475","doi-asserted-by":"crossref","first-page":"25338","DOI":"10.1038\/s41598-025-10143-6","article-title":"TGF\u03b21 accelerated the progression of diabetic nephropathy via up-regulating BRD4\/Notch1\/YAP signaling induced fibrosis and proliferation in fibroblasts","volume":"15","author":"Li","year":"2025","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1535370215597194","article-title":"Epithelial-mesenchymal transition: An emerging target in tissue fibrosis","volume":"241","author":"Li","year":"2016","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0485","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1186\/s12967-025-06778-8","article-title":"The type I collagen paradox in PDAC progression: Microenvironmental protector turned tumor accomplice","volume":"23","author":"Li","year":"2025","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0495","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s11064-024-04112-0","article-title":"Inhibition of CK2 diminishes fibrotic scar formation and improves outcomes after ischemic stroke via reducing BRD4 phosphorylation","volume":"49","author":"Li","year":"2024","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148126","article-title":"Inhibition of BRD4 decreases fibrous scarring after ischemic stroke in rats by inhibiting the phosphorylation of Smad2\/3","volume":"1797","author":"Li","year":"2022","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0510","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41589-024-01668-4","article-title":"Template-assisted covalent modification underlies activity of covalent molecular glues","volume":"20","author":"Li","year":"2024","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0515","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.apsb.2020.12.012","article-title":"The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0520","article-title":"A real-world retrospective study of romidepsin: Insights from the Food and Drug Administration adverse event reporting system","volume":"105","author":"Liang","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0525","article-title":"Epigenetic reader bromodomain containing protein 2 facilitates pathological cardiac hypertrophy via regulating the expression of citrate cycle genes","volume":"13","author":"Lin","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ijc.33989","article-title":"Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses","volume":"151","author":"Liu","year":"2022","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101195","article-title":"Inhibition of Brd4 alleviates renal ischemia\/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress","volume":"24","author":"Liu","year":"2019","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.102134","article-title":"Involvement of BRD4 in alcoholic liver injury: Autophagy modulation via regulation of the SIRT1\/Beclin1 Axis","volume":"104","author":"Liu","year":"2024","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0545","article-title":"Post-translational modifications of BRD4: Therapeutic targets for tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0550","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","article-title":"Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release","volume":"155","author":"Liu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0555","first-page":"101","article-title":"The BRD4 inhibitor JQ1 protects against chronic obstructive pulmonary disease in mice by suppressing NF-\u03baB activation","volume":"36","author":"Liu","year":"2021","journal-title":"Histology and Histopathology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0560","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/jcp.26010","article-title":"Biological function and histone recognition of family IV bromodomain-containing proteins","volume":"233","author":"Lloyd","year":"2018","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0565","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052617","article-title":"The pathogenesis of cardiac fibrosis: A review of recent Progress","volume":"23","author":"Maruyama","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0575","doi-asserted-by":"crossref","first-page":"17257","DOI":"10.1038\/s41598-018-35653-4","article-title":"BET inhibition improves NASH and liver fibrosis","volume":"8","author":"Middleton","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological Actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.08.001","article-title":"DNA methylation as a transcriptional regulator of the immune system","volume":"204","author":"Morales-Nebreda","year":"2019","journal-title":"Translational Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010486","article-title":"Type IV collagen and SOX9 are molecular targets of BET inhibition in experimental glomerulosclerosis","volume":"24","author":"Morgado-Pascual","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0595","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jacbts.2023.01.014","article-title":"Platelet-derived growth factors: A new therapeutic opportunity for treating cardiac fibrosis?","volume":"8","author":"Mouton","year":"2023","journal-title":"JACC Basic Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0600","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/sj.onc.1210618","article-title":"Structure and acetyl-lysine recognition of the bromodomain","volume":"26","author":"Mujtaba","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0605","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0610","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1158\/1535-7163.MCT-24-0219","article-title":"Discovery of monovalent direct degraders of BRD4 that act via the recruitment of DCAF11","volume":"23","author":"Parker","year":"2024","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0615","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/MCB.01180-12","article-title":"BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF\/DSIF to regulate transcription elongation of interferon-stimulated genes","volume":"33","author":"Patel","year":"2013","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/biom16010103","article-title":"Epigenetic dysregulation in neurodegeneration: The role of histone deacetylases and emerging inhibitor strategies","volume":"16","author":"Pawar","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0625","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41586-025-08671-2","article-title":"Evolutionary fingerprints of epithelial-to-mesenchymal transition","volume":"640","author":"Perelli","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0630","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bbrc.2016.05.140","article-title":"Epigenetic dysregulation of interleukin 8 (CXCL8) hypersecretion in cystic fibrosis airway epithelial cells","volume":"476","author":"Poghosyan","year":"2016","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0635","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3727\/105221618X15205148413587","article-title":"Hepatocyte Wnts are dispensable during diethylnitrosamine and carbon tetrachloride-induced injury and hepatocellular Cancer","volume":"18","author":"Preziosi","year":"2018","journal-title":"Gene Expression"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248784","article-title":"Proteomic insights into cardiac fibrosis: From pathophysiological mechanisms to therapeutic opportunities","volume":"27","author":"Qi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0645","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.tcb.2024.01.006","article-title":"Functional analysis of cell plasticity using single-cell technologies","volume":"34","author":"Qin","year":"2024","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0650","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1164\/rccm.201711-2242OC","article-title":"Reversing mechanoinductive DSP expression by CRISPR\/dCas9-mediated epigenome editing","volume":"198","author":"Qu","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0655","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41420-018-0066-1","article-title":"BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring","volume":"4","author":"Qu","year":"2018","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0660","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0665","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cytogfr.2020.08.004","article-title":"Targeting chromatin dysregulation in organ fibrosis","volume":"57","author":"Rani","year":"2021","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0670","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ndt\/gfw157.09","article-title":"SP048THE bet BROMODOMAIN inhibitor JQ1 diminished renal fibrosis","volume":"31","author":"Rayego-Mateos","year":"2016","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249620","article-title":"Inhibition of BRD4 reduces neutrophil activation and adhesion to the vascular endothelium following ischemia reperfusion injury","volume":"21","author":"Reid","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0680","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1139\/cjpp-2019-0142","article-title":"Role of Brd4 in the production of inflammatory cytokines in mouse macrophages treated with titanium particles","volume":"97","author":"Ren","year":"2019","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0685","doi-asserted-by":"crossref","first-page":"84675","DOI":"10.18632\/oncotarget.13181","article-title":"OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations","volume":"7","author":"Riveiro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0690","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1078155216673229","article-title":"Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature","volume":"24","author":"Rivers","year":"2018","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116492","article-title":"BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury","volume":"174","author":"Saiz","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0700","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137127","article-title":"Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice","volume":"5","author":"Sanders","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0705","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*","volume":"85","author":"Santini","year":"2010","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102683","article-title":"Apabetalone, a clinical-stage, selective BET inhibitor, opposes DUX4 target gene expression in primary human FSHD muscle cells","volume":"11","author":"Sarsons","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0715","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.resinv.2023.08.003","article-title":"A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect","volume":"61","author":"Sato","year":"2023","journal-title":"Respiratory Investigation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0720","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s13311-013-0204-7","article-title":"Acetyltransferases (HATs) as targets for neurological therapeutics","volume":"10","author":"Schneider","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0725","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-025-60424-x","article-title":"CRISPR screen decodes SWI\/SNF chromatin remodeling complex assembly","volume":"16","author":"Schwaemmle","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/cells15020118","article-title":"BRD4 phosphorylation regulates the structure of chromatin nanodomains","volume":"15","author":"Seitz","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0735","doi-asserted-by":"crossref","first-page":"12453","DOI":"10.1093\/nar\/gkaa1000","article-title":"Epigenome engineering: New technologies for precision medicine","volume":"48","author":"Sgro","year":"2020","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0740","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1242\/dev.004481","article-title":"The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation","volume":"134","author":"Shang","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47050297","article-title":"The mechanical role of YAP\/TAZ in the development of diabetic cardiomyopathy","volume":"47","author":"Shen","year":"2025","journal-title":"Current Issues in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0750","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/biom10121666","article-title":"Transforming growth factor-\u03b2 signaling in fibrotic diseases and Cancer-associated fibroblasts","volume":"10","author":"Shi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0760","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0790","article-title":"Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis","volume":"11","author":"Shin","year":"2019","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0765","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12931-025-03306-6","article-title":"An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis","volume":"26","author":"Skibba","year":"2025","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0770","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acschembio.8b00260","article-title":"Small molecule and pooled CRISPR screens investigating IL17 signaling identify BRD2 as a novel contributor to keratinocyte inflammatory responses","volume":"14","author":"Slivka","year":"2019","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0775","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2018.12.002","article-title":"Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-\u03b2-induced endothelial-mesenchymal transition and cardiac fibrosis","volume":"127","author":"Song","year":"2019","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176714","article-title":"BRD4 as a therapeutic target for atrial fibrosis and atrial fibrillation","volume":"977","author":"Song","year":"2024","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110363","article-title":"BET inhibitor JQ1 attenuates atrial fibrillation through modulation of fibrosis, calcium homeostasis, and mitochondrial function in a murine model","volume":"26","author":"Song","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107631","article-title":"Targeting BET bromodomain proteins in cancer: The example of lymphomas","volume":"215","author":"Spriano","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0795","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.yjmcc.2016.05.002","article-title":"Molecular networks underlying myofibroblast fate and fibrosis","volume":"97","author":"Stempien-Otero","year":"2016","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0800","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/MMBR.64.2.435-459.2000","article-title":"Acetylation of histones and transcription-related factors","volume":"64","author":"Sterner","year":"2000","journal-title":"Microbiology and Molecular Biology Reviews"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0805","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1484736","article-title":"Bromodomain and Extraterminal (BET) protein inhibition restores redox balance and inhibits myofibroblast activation","volume":"2019","author":"Stock","year":"2019","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0810","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0815","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/CIRCRESAHA.119.315125","article-title":"Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation","volume":"125","author":"Stratton","year":"2019","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0820","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.celrep.2016.06.074","article-title":"Signal-dependent recruitment of BRD4 to cardiomyocyte super-enhancers is suppressed by a MicroRNA","volume":"16","author":"Stratton","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0825","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","article-title":"Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis","volume":"11","author":"Strunz","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0830","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.2015080910","article-title":"Inhibition of bromodomain and extraterminal domain family proteins ameliorates experimental renal damage","volume":"28","author":"Suarez-Alvarez","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0835","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.physbeh.2016.08.036","article-title":"A single day of 5-azacytidine exposure during development induces neurodegeneration in neonatal mice and neurobehavioral deficits in adult mice","volume":"167","author":"Subbanna","year":"2016","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0840","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jare.2023.11.006","article-title":"Unlocking the secrets of aging: Epigenetic reader BRD4 as the target to combatting aging-related diseases","volume":"63","author":"Sun","year":"2024","journal-title":"Journal of Advanced Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0845","doi-asserted-by":"crossref","first-page":"F469","DOI":"10.1152\/ajprenal.00527.2017","article-title":"Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity","volume":"315","author":"Sun","year":"2018","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0850","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12320","article-title":"Inhibition of BRD4 attenuates cardiomyocyte apoptosis via NF-\u03baB pathway in a rat model of myocardial infarction","volume":"36","author":"Sun","year":"2018","journal-title":"Cardiovascular Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0855","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3892\/mmr.2020.11218","article-title":"Transcriptomic changes involved in the dedifferentiation of myofibroblasts derived from the lung of a patient with idiopathic pulmonary fibrosis","volume":"22","author":"Suzuki","year":"2020","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108681","article-title":"HDAC1\/2 inhibitor therapy improves multiple organ systems in aged mice","volume":"27","author":"Tammaro","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110712","article-title":"Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development","volume":"27","author":"Tan","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0875","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41419-020-2431-2","article-title":"Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis","volume":"11","author":"Tan","year":"2020","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0880","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajpath.2013.04.020","article-title":"Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis","volume":"183","author":"Tang","year":"2013","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0885","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/mol.112.081661","article-title":"BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis","volume":"83","author":"Tang","year":"2013","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0890","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111849","article-title":"The Bromodomain and Extra-Terminal domain (BET) family: Functional anatomy of BET paralogous proteins","volume":"17","author":"Taniguchi","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114153","article-title":"Discovery of indol-6-yl-pyrrolo[2,3-c]pyridin-7-one derivatives as bromodomain-containing protein 4 (BRD4) inhibitors for the treatment of kidney fibrosis","volume":"231","author":"Tao","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0900","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nature Methods"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0905","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1172\/JCI74368","article-title":"Fibrosis: Ultimate and proximate causes","volume":"124","author":"Thannickal","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0910","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11899-024-00744-9","article-title":"JAK inhibitors for myelofibrosis: Strengths and limitations","volume":"19","author":"Thaw","year":"2024","journal-title":"Current Hematologic Malignancy Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0915","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaci.2018.09.029","article-title":"Mucosal bromodomain-containing protein 4 mediates aeroallergen-induced inflammation and remodeling","volume":"143","author":"Tian","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0920","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1165\/rcmb.2017-0445OC","article-title":"Efficacy of novel highly specific bromodomain-containing protein 4 inhibitors in innate inflammation-driven airway remodeling","volume":"60","author":"Tian","year":"2019","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0925","doi-asserted-by":"crossref","first-page":"L1183","DOI":"10.1152\/ajplung.00224.2016","article-title":"BRD4 mediates NF-\u03baB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation","volume":"311","author":"Tian","year":"2016","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0930","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201263R","article-title":"Early-immediate gene Egr1 is associated with TGF\u03b21 regulation of epigenetic reader bromodomain-containing protein 4 via the canonical Smad3 signaling in hepatic stellate cells in vitro and in vivo","volume":"36","author":"Tian","year":"2022","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0935","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0940","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","article-title":"Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension","volume":"200","author":"Van der Feen","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0945","article-title":"Cardiac fibroblasts in myocardial injury and heart failure","author":"Van Linthout","year":"2025","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102811","article-title":"Emerging strategies for prospective discovery of molecular glue degraders","volume":"86","author":"Wang","year":"2024","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0960","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41598-018-19343-9","article-title":"Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis","volume":"8","author":"Wang","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107306","article-title":"Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300\/H3K27ac\/PLK1 axis","volume":"207","author":"Wang","year":"2024","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0970","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105804","article-title":"Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms","volume":"172","author":"Wang","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111507","article-title":"Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition","volume":"383","author":"Wang","year":"2019","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0985","article-title":"The real-world analysis of adverse events with azacitidine: A pharmacovigilance study based on the FAERS and WHO-VigiAccess databases","volume":"16","author":"Wang","year":"2025","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0990","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: Biological functions, diseases and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb0995","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ekir.2017.12.001","article-title":"Benefit of apabetalone on plasma proteins in renal disease","volume":"3","author":"Wasiak","year":"2018","journal-title":"Kidney International Report"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1000","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40364-024-00641-6","article-title":"BRD4: An effective target for organ fibrosis","volume":"12","author":"Wei","year":"2024","journal-title":"Biomarker Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2213-2600(20)30062-X","article-title":"Progress in the treatment of pulmonary fibrosis","volume":"8","author":"Wijsenbeek","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1010","series-title":"Abstract 133: Selective Bromodomain inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 CVOT Study","first-page":"A133","volume":"40","author":"Wong","year":"2020"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-0716-4051-7_14","article-title":"Protocol for delivery of CRISPR\/dCas9 systems for epigenetic editing into solid tumors using lipid nanoparticles encapsulating RNA","volume":"2842","author":"Woodward","year":"2024","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1020","article-title":"Hepatic BRD4 is upregulated in liver fibrosis of various etiologies and positively correlated to fibrotic severity","volume":"8","author":"Wu","year":"2021","journal-title":"Frontier in Medicine (Lausanne)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1025","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1030","doi-asserted-by":"crossref","first-page":"L690","DOI":"10.1152\/ajplung.00500.2017","article-title":"JQ1 is a potential therapeutic option for COPD patients with agrin overexpression","volume":"314","author":"Xiao","year":"2018","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.636154","article-title":"Pharmacologic targeting of BET proteins attenuates hyperuricemic nephropathy in rats","volume":"12","author":"Xiong","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1040","doi-asserted-by":"crossref","first-page":"69291","DOI":"10.18632\/oncotarget.12498","article-title":"Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis","volume":"7","author":"Xiong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1045","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1038\/s41467-025-63167-x","article-title":"Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins","volume":"16","author":"Xu","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.toxlet.2023.08.009","article-title":"Bromodomain protein 4 mediates the roles of TGF\u03b21-induced Stat3 signaling in mouse liver fibrogenesis","volume":"385","author":"Xu","year":"2023","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105910","article-title":"Epigenetic regulation in fibrosis progress","volume":"173","author":"Xue","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1060","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.metabol.2016.07.001","article-title":"BRD4 regulates fructose-inducible lipid accumulation-related genes in the mouse liver","volume":"65","author":"Yamada","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105594","article-title":"Ubiquitin-specific protease 22 ameliorates chronic alcohol-associated liver disease by regulating BRD4","volume":"168","author":"Yan","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial-mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Yang","year":"2005","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1080","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1097-2765(03)00388-5","article-title":"Inhibition of P-TEFb (CDK9\/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA","volume":"12","author":"Yik","year":"2003","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymthe.2025.08.047","article-title":"Epigenome editing based treatment: Progresses and challenges","volume":"34","author":"Yuan","year":"2026","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1090","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.7150\/thno.113852","article-title":"Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1095","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","article-title":"Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4","volume":"24","author":"Zanconato","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1100","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: Causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1644792","article-title":"Inhibition of BRD4 prevents peribronchial fibrosis in mice with cutaneous lewisite exposure","volume":"12","author":"Zeng","year":"2025","journal-title":"Frontiers in Molecular Biosciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1110","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.cell.2025.08.033","article-title":"Epithelial-mesenchymal transition","volume":"188","author":"Zhang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1115","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","article-title":"Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets","volume":"22","author":"Zhang","year":"2016","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1120","article-title":"Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1125","article-title":"Histone deacetylases and their inhibitors in inflammatory diseases","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tips.2025.09.006","article-title":"Targeting BRD4 bromodomains and beyond: Exploring new therapeutic frontiers","volume":"47","author":"Zhang","year":"2026","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1135","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells","volume":"287","author":"Zhang","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1140","article-title":"A novel paradigm for targeting challenging targets: Advancing technologies and future directions of molecular glue degraders","volume":"31","author":"Zhang","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102531","article-title":"BRD4 absence inactivates endoplasmic reticulum stress to retard dehydroepiandrosterone-triggered ovarian granular cell apoptosis in polycystic ovary syndrome via GRP78","volume":"91","author":"Zhang","year":"2024","journal-title":"Tissue & Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/978-981-13-8871-2_33","article-title":"Antifibrotic roles of RAAS blockers: Update","volume":"1165","author":"Zhang","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1155","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.apsb.2021.10.016","article-title":"Prmt1 upregulated by Hdc deficiency aggravates acute myocardial infarction via NETosis","volume":"12","author":"Zhang","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and cilinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation","volume":"83","author":"Zheng","year":"2023","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: Advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1180","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.redox.2016.12.031","article-title":"Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-\u03b2-mediated Nox4 expression","volume":"11","author":"Zhou","year":"2017","journal-title":"Redox Biology"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41420-023-01563-2","article-title":"Bellidifolin ameliorates isoprenaline-induced cardiac hypertrophy by the Nox4\/ROS signalling pathway through inhibiting BRD4","volume":"9","author":"Zhou","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109368","article-title":"BRD4 blockage alleviates pathological cardiac hypertrophy through the suppression of fibrosis and inflammation via reducing ROS generation","volume":"121","author":"Zhu","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117887","article-title":"Design, synthesis, and biological evaluation of a dual-action agent targeting bromodomain and extraterminal domain and H(2)S release for the treatment of hepatic and pulmonary injury","volume":"296","author":"Zhu","year":"2025","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1200","article-title":"Identification of A p300-SP1-BRD4 transcriptional Axis as a key driver of AR hyperactivation in polycystic ovarian syndrome","author":"Zhu","year":"2026","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109055_bb1205","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202508427","article-title":"Rational design of CDK12\/13 and BRD4 molecular glue degraders","volume":"64","author":"Zhuang","year":"2025","journal-title":"Angewandte Chemie (International Ed. in English)"}],"updated-by":[{"DOI":"10.1016\/j.pharmthera.2026.109082","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000}},{"DOI":"10.1016\/j.pharmthera.2026.109082","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:12:41Z","timestamp":1786486361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":238,"alternative-id":["S0163725826000823"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109055","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BRD4 to reverse organ fibrosis: Epigenetic regulation, cellular plasticity, and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109055"}}